Vaud-based biopharma Oculis has secured USD 59 million to extend operations into 2026, following a successful listing on NASDAQ Iceland Main Market.
Oculis Holding AG, a leading global biopharmaceutical company focused on saving sight and improving eye care, has announced a successful financing round and its subsequent listing on the NASDAQ Iceland Main Market. The Vaud-based company, known for its innovative ophthalmic treatments, raised approximately USD 59 million through the issuance of 5,000,000 ordinary shares at a purchase price of USD 11.75 per share.
The completion of this registered direct offering marks a pivotal moment for Oculis, which is dual-listed in the U.S. and now in Iceland, where its proprietary OPTIREACH® technology was developed. “We are pleased to become one of the few dual-listed biotech companies in the U.S. as well as Iceland,” stated Riad Sherif, M.D., CEO of Oculis. He expressed gratitude towards the new investor syndicate for their support and shared excitement about the upcoming topline results from the OCS-02 Phase 2b RELIEF trial in Dry Eye Disease (DED), expected later this quarter.
This financial milestone follows Oculis’s significant achievements, including its Nasdaq Global Market listing in 2023, under the ticker symbol “OCS.” The company has been a fixture in the international biopharmaceutical landscape, contributing innovative product candidates for critical ophthalmic conditions.
Transformative therapies for eye diseases
The proceeds from the offering are designated for advancing Oculis’s clinical development pipeline, alongside general corporate purposes. The company estimates these funds will sustain its operations and capital expenditure needs into the second half of 2026.
Oculis’ prospectus for admission of its shares on the NASDAQ Iceland Main Market was approved by the Central Bank of Iceland, highlighting the company’s robust regulatory and financial standing.
Arctica Finance ehf. managed the process oversight for the listing, while BBA//Fjeldco, Cooley LLP, and Vischer AG served as legal advisors. This strategic financial maneuver not only underscores Oculis’s solid market position but also reinforces its commitment to developing transformative therapies for eye diseases, aiming to extend significant value to patients, physicians, and investors worldwide.
